Literature DB >> 19347848

The immune response to tumors.

Michael Dougan1, Glenn Dranoff.   

Abstract

The immune response to tumors is complex. Cells of the immune system can inhibit tumor growth and progression through the recognition and rejection of malignant cells, a process referred to as immunoediting. Yet, immune responses can also promote tumor cell growth, survival, and angiogenesis through the induction of oncogenic inflammation. Immunodeficiency can predispose to the development of spontaneous and virally induced cancer, and established tumors often generate immunosuppressive microenvironments that can block productive antitumor immunity, serving as a substantial barrier to effective immune therapy. Through a deeper understanding of the complicated relationship between tumors and the immune system, tumor immunology strives to harness the immune system to generate protective antitumor responses in patients. Copyright 2009 by John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19347848     DOI: 10.1002/0471142735.im2011s85

Source DB:  PubMed          Journal:  Curr Protoc Immunol        ISSN: 1934-3671


  11 in total

1.  CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation.

Authors:  Kavya Rakhra; Pavan Bachireddy; Tahera Zabuawala; Robert Zeiser; Liwen Xu; Andrew Kopelman; Alice C Fan; Qiwei Yang; Lior Braunstein; Erika Crosby; Sandra Ryeom; Dean W Felsher
Journal:  Cancer Cell       Date:  2010-10-28       Impact factor: 31.743

Review 2.  NF-kappaB fans the flames of lung carcinogenesis.

Authors:  Kwok-Kin Wong; Tyler Jacks; Glenn Dranoff
Journal:  Cancer Prev Res (Phila)       Date:  2010-03-30

3.  T cell density and location can influence the prognosis of ovarian cancer.

Authors:  Ahmad Al-Attar; Mohamed Shehata; Lindy Durrant; Paul Moseley; Suha Deen; Stephen Chan
Journal:  Pathol Oncol Res       Date:  2009-12-19       Impact factor: 3.201

Review 4.  Cytotoxic and regulatory properties of circulating Vδ1+ γδ T cells: a new player on the cell therapy field?

Authors:  Gabrielle M Siegers; Lawrence S Lamb
Journal:  Mol Ther       Date:  2014-06-04       Impact factor: 11.454

5.  A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40.

Authors:  Jingtao Chen; Gerard Zurawski; Sandy Zurawski; Zhiqing Wang; Keiko Akagawa; Sangkon Oh; Ueno Hideki; Joseph Fay; Jacques Banchereau; Wenru Song; A Karolina Palucka
Journal:  J Hematol Oncol       Date:  2015-04-14       Impact factor: 17.388

Review 6.  Immunotherapy for Lung Cancer: Has it Finally Arrived?

Authors:  Ahmed A Mostafa; Don G Morris
Journal:  Front Oncol       Date:  2014-10-22       Impact factor: 6.244

7.  Deficiency of AMPK in CD8+ T cells suppresses their anti-tumor function by inducing protein phosphatase-mediated cell death.

Authors:  Enyu Rao; Yuwen Zhang; Ganqian Zhu; Jiaqing Hao; Xuan-Mai T Persson; Nejat K Egilmez; Jill Suttles; Bing Li
Journal:  Oncotarget       Date:  2015-04-10

Review 8.  Real-world impact of education: treating patients with ipilimumab in a community practice setting.

Authors:  Blanca Ledezma; Annie Heng
Journal:  Cancer Manag Res       Date:  2013-12-21       Impact factor: 3.989

9.  Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy.

Authors:  Hyo Min Ahn; JinWoo Hong; Chae-Ok Yun
Journal:  Oncotarget       Date:  2016-12-20

10.  Pretreatment platelet to lymphocyte ratio is predictive of overall survival in metastatic pancreatic ductal adenocarcinoma.

Authors:  Guanghai Dai; Xiaorong Li; Wanwan Li; Yang Chen; Xuelin Wang; Yan Shi
Journal:  Transl Cancer Res       Date:  2019-02       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.